Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Nobelpharma to Launch 3 New Drugs
February 18, 2008
- Survey／COPD Awareness Rate Remains Unchanged at 34%: NBI/Pfizer Survey
February 18, 2008
- Takara Bio to Launch World's First Protein Regulation System
February 18, 2008
- GENERICS NEWS IN BRIEF
February 18, 2008
- Korosho to Send Missions to the US, UK and France
February 18, 2008
- SELF-MEDICATION NEWS IN BRIEF
February 18, 2008
- JPMA to Cooperate in Reduction in CO2 Emission
February 18, 2008
- Requirements for Self-injection of IFN, Etanercept Relaxed
February 18, 2008
- BUSINESS NEWS IN BRIEF
February 18, 2008
- Kyushu Medical Association Decides to Support Dr Karasawa
February 18, 2008
- Herceptin Approved for Postoperative Adjuvant Chemotherapy
February 18, 2008
- Takeda to Use Amgen Japanas Development Subsidiary
February 18, 2008
- No Problems Found in EPPV of Velcade, Alimta
February 18, 2008
- Objection to Use of Literature by MRs without Obtaining Prior Consent
February 18, 2008
- REGULATORY NEWS IN BRIEF
February 18, 2008
- Takeda Begins PIII for Combination of Actos and DPP-4 Inhibitor
February 18, 2008
- Successor of Prograf Will Not Reach US Market before Expiration of Its Patent
February 18, 2008
- TMDU, Nippon Chemiphar Report Efficacy of NC-2300 for Autoimmune Disease
February 18, 2008
- CDK Inhibitors Are Also Effective for RA
February 18, 2008
- R&D NEWS IN BRIEF
February 18, 2008
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…